W.R. Berkley Q3 Profit Falls While Operating EPS Rises
Berkley reported $446.0 million in net income available to common shareholders, down from $511.0 million. Its separately defined non-GAAP operating EPS rose to $1.17.
Capital-markets reporting focused on the United States.
Berkley reported $446.0 million in net income available to common shareholders, down from $511.0 million. Its separately defined non-GAAP operating EPS rose to $1.17.
Tegria announced its acquisition of healthcare cloud and cybersecurity provider CloudWave on October 19. The issuer announcement does not disclose a purchase price or financial accretion estimate.
Zions reported diluted EPS of $1.78, up from $1.48 a year earlier. A credit-loss provision benefit supported earnings, while net interest margin narrowed.
Diluted EPS rose to $2.45 as net interest margin improved to 3.57%. Nonaccrual loans fell, but the bank continued adding to credit-loss reserves.
Common-shareholder income reached $828 million, while reported diluted EPS was $0.90 versus $0.91 a year earlier. The results include Comerica and require like-for-like caution.
Diluted EPS rose to $0.80 from $0.60 on the company’s retrospectively split-adjusted basis. Net interest income increased, while margin was unchanged from Q2.
CoastalSouth reported diluted EPS of $0.71 and declared a $0.06-per-share dividend. November 10 is the record date and November 24 the scheduled payment date.
RBB reported $12.6 million net income and $0.74 diluted EPS, with a building-sale gain included. Its $0.16 common-share dividend is payable November 12.
The proposed cash-and-equity deal would expand Tradeweb’s bond-trading business. Regulatory approvals remain pending, with closing targeted for the first half of 2027.
Reported diluted EPS was $1.11, up from $1.07 a year earlier. The sequential comparison is affected by a consulting charge recorded in Q2.
Silgan and AIP plan a metal-packaging partnership with 60% and 40% ownership respectively. The proposed Trivium acquisition targets closing in mid-2027.
The proposed purchase would expand Hologic’s breast-cancer diagnostics portfolio. The official release does not disclose a price or closing date, and Spanish regulatory approval remains necessary.
Start with three recent reports, then explore the facts, sources and practical context. No political coverage. No promises of investment returns.
Questions or corrections? Contact the newsroom.